X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0%
Mon, 13 Aug

AUROBINDO PHARMA has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-17*
3
Mar-18*
3
Jun-18*
QoQ ChangeYoY Change
Net SalesRs m36,78840,49142,5035.0%15.5%
Other incomeRs m333438437-0.2%31.5%
TurnoverRs m37,12040,92942,9404.9%15.7%
ExpensesRs m28,56032,61035,3928.5%23.9%
Gross profitRs m8,2287,8847,111-9.8%-13.6%
DepreciationRs m1,3121,5661,545-1.3%17.8%
InterestRs m16924729519.5%75.1%
Profit before taxRs m7,0806,5095,707-12.3%-19.4%
TaxRs m1,9101,2241,155-5.6%-39.5%
Profit after taxRs m5,1705,2854,552-13.9%-12.0%
Gross profit margin%22.419.516.7
Effective tax rate%27.018.820.2
Net profit margin%13.912.910.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 15.5% on a year-on-year (YoY) basis. The expenses were up by 23.9% YoY during the same period.
  • The company's operating profit declined by 13.6% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 16.7% in 1QFY19 as against 22.4% in 1QFY18.
  • Depreciation charges and finance costs increased by 17.8% YoY and 75.1% YoY, respectively.
  • Other income increased by 31.5% YoY during the quarter.
  • Net profit for the quarter declined by 12.0% YoY. Net profit margins during the quarter declined from 13.9% in 1QFY18 to 10.6% in 1QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 5.0% on a quarter-on-quarter (QoQ) basis. The expenses were up by 8.5% QoQ during the same period.
  • The company's operating profit declined by 9.8% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 16.7% in 1QFY19 as against 19.5% in 4QFY18.
  • Net profit for the quarter declined by 13.9% QoQ, while net profit margins declined from 12.9% in 4QFY18 to 10.6% in 1QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 704.8 to Rs 617.0, registering a Loss of Rs 87.9 or around 12.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,318.8 (up 0.5%). Over the last one year it has moved up from 12,807.8 to 14,318.8, a gain of 1,511 points (up 11.8%).

Overall, the S&P BSE SENSEX is up 19.3% over the year.

Current Valuations

At the current price of Rs 617.0, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 15.3 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.9 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 10, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS